白蛋白结合型紫杉醇联合奥沙利铂、低剂量替吉奥治疗老年晚期贲门癌的效果及对肿瘤标志物、Hsp90α、CXCL4水平的影响

Effect of albumin-binding paclitaxel combined with oxaliplatin and low-dose tegafur in the treatment of elderly patients with advanced cardiac cancer and its influences on tumor markers,Hsp90αand CXCL4 levels

目的探究白蛋白结合型紫杉醇联合奥沙利铂、低剂量替吉奥治疗老年晚期贲门癌的效果及对肿瘤标志物、热休克蛋白90α(Hsp90α)、血小板趋化因子CXCL4水平的影响。方法选择2019年1月至2021年11月我院收治的70例老年晚期贲门癌患者作为研究对象,根据治疗方案不同将其分为对照组(35例,奥沙利铂、低剂量替吉奥治疗)和观察组(35例,在对照组基础上加白蛋白结合型紫杉醇治疗)。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的癌胚抗原(CEA)、甲胎蛋白(AFP)、神经元特异性烯醇化酶(NSE)、糖类抗原125(CA125)、糖类抗原199(CA199)水平低于治疗前,差异具有统计学意义(P<0.05);治疗后,观察组的CEA、AFP、NSE、CA125、CA199水平低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的Hsp90α、CXCL4水平低于治疗前,差异具有统计学意义(P<0.05);治疗后,观察组的Hsp90α、CXCL4水平低于对照组,差异具有统计学意义(P<0.05)。观察组的不良反应总发生率低于对照组,差异具有统计学意义(P<0.05)。治疗后6个月,两组的世界卫生组织生存质量测定量表简表(WHOQOL-BREF)各维度评分高于治疗前,差异具有统计学意义(P<0.05);治疗后6个月,观察组的WHOQOL-BREF各维度评分高于对照组,差异具有统计学意义(P<0.05)。结论白蛋白结合型紫杉醇联合低剂量奥沙利铂、替吉奥治疗老年晚期贲门癌的效果显著,有利于改善肿瘤标志物及Hsp90α、CXCL4水平,提高生活质量,值得临床推广和应用。

Objective To explore the effect of albumin-binding paclitaxel combined with oxaliplatin and low-dose tegafur in the treatment of elderly patients with advanced cardiac cancer and its influences on tumor markers,heat shock protein 90α(Hsp90α)and platelet chemotactic factor CXCL4 levels.Methods A total of 70 elderly patients with advanced cardia cancer admitted in our hospital from January 2019 to November 2021 were selected as the research objects.According to different treatment schemes,the patients were divided into control group(35 cases,treated with oxaliplatin and low-dose tegafur)and observation group(35 cases,treated with albumin-binding paclitaxel on the basis of the control group).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),alpha fetoprotein(AFP),neuron-specific enolase(NSE),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05);after treatment,the levels of CEA,AFP,NSE,CA125 and CA199 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of Hsp90αand CXCL4 in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05);after treatment,the levels of Hsp90αand CXCL4 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).At 6 months after treatment,the each dimension scores of the World Health Organization's Quality of Life Questionnaire-Brief Version(WHOQOL-BREF)in the two groups were higher than those before treatment,and the differences were statistically significant(P<0.05);at 6 months after treatment,the each dimension scores of WHOQOL-BREF in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Albumin-binding paclitaxel combined with oxaliplatin and low-dose tegafur is effective in the treatment of advanced cardiac cancer in the elderly.It is beneficial to improve the levels of tumor markers,Hsp90αand CXCL4,and increase the quality of life,which is worthy of clinical promotion and application.